Mounjaro vs Wegovy Results UK | Clinical Evidence 2025

Clinically Proven UK Registered Pharmacy

Mounjaro vs Wegovy Results - Cheapest UK Price £124.99

Compare Mounjaro and Wegovy weight loss results at the cheapest UK price from £124.99 plus £20 off with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off first order using code WEIGHTLOSSNEW
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£89.00 From £69.00 £10 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation

Mounjaro vs Wegovy Weight Loss Results: UK Clinical Evidence

When comparing mounjaro vs wegovy weight loss results uk, clinical trial data shows distinct differences in efficacy and mechanism. At Cured Pharmacy, our UK-registered clinical team helps patients understand these evidence-based outcomes to choose the most appropriate treatment, with transparent pricing from £135.00 and free online consultation under three minutes.

Clinical Trial Results: Mounjaro vs Wegovy Weight Loss Outcomes

The most rigorous head-to-head comparison comes from the SURPASS-2 trial, which directly compared tirzepatide (Mounjaro) against semaglutide 1mg in adults with type 2 diabetes. Participants receiving the highest tirzepatide dose (15mg) achieved an average body weight reduction of 11.2kg, compared to 5.7kg with semaglutide 1mg over 40 weeks [1]. This represents nearly double the weight loss with tirzepatide's dual-receptor mechanism.

In obesity-specific trials, the SURMOUNT-1 study demonstrated that Mounjaro produced average weight reductions of up to 22.5% of initial body weight over 72 weeks at the 15mg maintenance dose [2]. By comparison, the STEP-1 trial showed Wegovy (semaglutide 2.4mg) achieved average reductions of 14.9% over 68 weeks [3]. Both medications significantly outperformed placebo and lifestyle intervention alone, but tirzepatide consistently demonstrated superior efficacy across multiple endpoints.

It's important to note that individual responses vary considerably based on adherence, baseline metabolic health, and lifestyle factors. Your UK prescriber at Cured Pharmacy will assess your medical history, current medications, and weight loss goals to determine which treatment may be most appropriate for your circumstances.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA in the UK. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, creating a synergistic effect on appetite regulation, insulin secretion, and gastric emptying [1]. This dual mechanism appears to produce greater metabolic benefits than GLP-1 activation alone.

Wegovy contains semaglutide, a selective GLP-1 receptor agonist that has been extensively studied since its approval. Semaglutide works by mimicking the natural GLP-1 hormone, which reduces appetite through central nervous system pathways, slows gastric emptying, and improves glycaemic control [3]. While operating through a single pathway, semaglutide demonstrates robust efficacy and has the longest track record of real-world safety data among weekly injectable weight loss treatments.

Both medications require once-weekly subcutaneous injection and follow dose escalation schedules to minimise gastrointestinal side effects. The choice between them often depends on individual response, tolerability, cost considerations, and prescriber assessment of your clinical profile.

Mechanism of Action: Why Dual Receptors May Offer Advantages

The addition of GIP receptor activation in tirzepatide appears to enhance fat metabolism and may reduce the gastrointestinal side effects commonly associated with GLP-1 agonists alone [2]. Preclinical studies suggest GIP improves insulin sensitivity in adipose tissue and may influence energy expenditure, though the exact mechanisms in humans continue to be investigated.

Clinical observations show that patients on tirzepatide often report better tolerability at higher doses compared to maximum-dose semaglutide, though individual experiences vary significantly. This may relate to the modulatory effect of GIP on gastric motility, potentially offsetting some of the nausea and vomiting associated with strong GLP-1 activation.

Mounjaro vs Wegovy: Side Effect Profiles and Tolerability

Both Mounjaro and Wegovy share similar side effect profiles, with gastrointestinal symptoms being most common. In clinical trials, nausea occurred in approximately 20-30% of participants on both medications, typically during dose escalation phases [1][3]. Diarrhoea, constipation, vomiting, and abdominal discomfort were also frequently reported, though most symptoms were mild to moderate and diminished over time.

The SURPASS trials showed that discontinuation rates due to adverse events were comparable between tirzepatide and semaglutide, ranging from 4-7% depending on dose [1]. Importantly, serious adverse events were rare with both treatments. However, both medications carry warnings for potential thyroid C-cell tumours based on rodent studies, and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

At Cured Pharmacy, our UK prescribers conduct thorough medical assessments to identify contraindications and ensure appropriate monitoring. All patients receive detailed guidance on managing side effects, recognising warning signs, and when to seek medical attention. Both treatments require gradual dose titration, which significantly reduces the severity of initial gastrointestinal symptoms.

Managing Common Side Effects

Most gastrointestinal side effects can be minimised by eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. Taking the injection on the same day each week and following the prescribed dose escalation schedule without rushing helps your body adapt to the medication gradually.

If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to the back), contact your prescriber immediately. Both medications have been associated with rare cases of acute pancreatitis, and any concerning symptoms require prompt medical evaluation.

Factor Mounjaro (Tirzepatide) Wegovy (Semaglutide)
Mechanism Dual GIP/GLP-1 receptor agonist GLP-1 receptor agonist
Dosing frequency Once weekly injection Once weekly injection
Maximum dose 15mg weekly 2.4mg weekly
Average weight loss (trials) Up to 22.5% over 72 weeks 14.9% over 68 weeks
Starting price at Cured Pharmacy From £69.00 From £69.00
Common side effects Nausea, diarrhoea, vomiting Nausea, diarrhoea, vomiting
MHRA approval for obesity Yes (2023) Yes (2021)

Cost Comparison: Mounjaro vs Wegovy Pricing at Cured Pharmacy

Pricing transparency is essential when considering long-term weight management treatments. At Cured Pharmacy, Mounjaro is available from £124.99 per month, while Wegovy starts from £135.00, with final costs determined by your prescribed maintenance dose following clinical assessment. Unlike some providers, we display upfront pricing before you complete your consultation, ensuring no unexpected costs.

The price difference reflects several factors, including manufacturing costs, market positioning, and supply chain considerations. Mounjaro, as the newer dual-receptor agonist, typically commands higher pricing across UK pharmacies. However, when evaluating cost-effectiveness, patients should consider the potentially greater weight loss outcomes demonstrated in clinical trials, which may justify the additional investment for some individuals.

Both treatments represent significant ongoing expenses, as weight management typically requires continuous therapy to maintain results. Our clinical team can discuss your budget considerations alongside clinical factors to identify the most appropriate and sustainable treatment plan. All prescription medications at Cured Pharmacy require online clinical assessment by a UK-registered prescriber, completed in under three minutes.

Who Should Choose Mounjaro vs Wegovy?

Clinical guidelines in the UK recommend GLP-1 receptor agonists for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. Both Mounjaro and Wegovy meet NICE criteria for weight management when prescribed alongside reduced-calorie diet and increased physical activity.

Mounjaro may be particularly suitable for patients who have not achieved adequate weight loss with semaglutide-based treatments, those with concurrent type 2 diabetes requiring robust glycaemic control, or individuals seeking maximum weight reduction based on clinical trial evidence. The dual-receptor mechanism offers a distinct pharmacological approach that some patients respond to more favourably.

Wegovy remains an excellent first-line option for most patients, particularly those concerned about cost, seeking a treatment with extensive real-world safety data, or who have previously tolerated GLP-1 agonists well. Many patients achieve significant, sustained weight loss with semaglutide 2.4mg, and it represents the most studied weekly injectable weight loss medication available in the UK.

Your Cured Pharmacy prescriber will evaluate your complete medical history, previous weight loss attempts, concurrent medications, and individual goals to recommend the most appropriate treatment. Factors such as kidney function, history of pancreatitis, diabetic retinopathy status, and cardiovascular risk profile all influence treatment selection.

Switching Between Treatments

Some patients may transition from Wegovy to Mounjaro if weight loss plateaus or side effects become problematic. Conversely, others may step down from Mounjaro to Wegovy for cost reasons once initial weight loss goals are achieved. Any treatment switch should be supervised by your prescriber to ensure appropriate dosing transitions and continued safety monitoring.

There is no required washout period when switching between semaglutide and tirzepatide, as both have similar pharmacokinetic profiles. Your prescriber will determine the appropriate starting dose based on your current treatment and tolerance, typically beginning at a lower dose to reassess tolerability with the new medication.

Long-Term Weight Maintenance: What the Evidence Shows

Extension studies from both the STEP and SURMOUNT programmes demonstrate that weight loss is maintained as long as treatment continues, but significant weight regain occurs upon discontinuation [2][3]. In the STEP-4 trial, participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks, highlighting the chronic nature of obesity and the need for ongoing pharmacological support.

This underscores an important clinical reality: both Mounjaro and Wegovy are long-term treatments rather than short-term interventions. The MHRA licensing and NICE guidance reflect this understanding, positioning these medications as chronic disease management tools similar to treatments for hypertension or diabetes. Patients should approach these treatments with realistic expectations about duration and commitment to lifestyle modifications.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide ongoing support throughout your weight management journey. We offer regular medication reviews, dose adjustments as needed, and guidance on integrating behavioural changes that support long-term success. Combining pharmacotherapy with sustainable dietary patterns and regular physical activity produces the best outcomes for lasting weight management.

Building Sustainable Habits Alongside Medication

While GLP-1 medications significantly reduce appetite and facilitate calorie restriction, they work best when combined with structured lifestyle interventions. Evidence suggests that patients who engage with dietetic support, establish regular exercise routines, and address psychological factors related to eating behaviours achieve superior long-term outcomes compared to medication alone.

Your prescriber can recommend NHS-approved weight management programmes, registered dietitians, and behavioural support resources to complement your pharmacological treatment. This integrated approach addresses obesity as the complex, multifactorial condition it is, rather than relying solely on medication to achieve lasting results.

Scientific References

  1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
  2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
  4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, lifestyle modifications, and individual metabolic factors. Clinical trial results represent average outcomes and do not guarantee specific results for any individual patient.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Which is better for weight loss, Mounjaro or Wegovy?
Clinical trials show Mounjaro (tirzepatide) produces greater average weight loss than Wegovy (semaglutide), with up to 22.5% reduction versus 14.9% in obesity studies. However, individual response varies, and your UK prescriber will recommend the most appropriate treatment based on your medical history, goals, and tolerability.
Can I switch from Wegovy to Mounjaro if I'm not losing enough weight?
Yes, switching from Wegovy to Mounjaro is possible under prescriber supervision if weight loss plateaus or is inadequate. Your Cured Pharmacy clinician will assess your progress and determine appropriate dosing for the transition, typically starting at a lower Mounjaro dose to evaluate tolerability.
How long does it take to see mounjaro vs wegovy weight loss results uk?
Most patients notice appetite reduction within the first week of either medication, with measurable weight loss typically evident by 4-8 weeks. Maximum weight loss usually occurs between 60-72 weeks of continuous treatment, following gradual dose escalation to maintenance levels.
Are Mounjaro and Wegovy available on the NHS?
Wegovy has limited NHS availability through specialist weight management services meeting strict criteria, while Mounjaro NHS access for weight loss remains restricted. Most UK patients access these treatments through private prescriptions from registered online pharmacies like Cured Pharmacy, where clinical assessment and dispensing occur within regulatory frameworks.
Do Mounjaro and Wegovy have the same side effects?
Both medications share similar gastrointestinal side effects including nausea, diarrhoea, vomiting, and constipation, occurring in 20-30% of patients during dose escalation. Discontinuation rates due to adverse events are comparable between the two treatments, typically 4-7% in clinical trials.
How much does mounjaro vs wegovy cost in the UK?
At Cured Pharmacy, Wegovy starts from £135.00 per month while Mounjaro starts from £124.99, with final costs depending on your prescribed maintenance dose. Both require ongoing treatment for sustained weight loss, making long-term cost considerations important when choosing between them.
Can I use Mounjaro or Wegovy if I have type 2 diabetes?
Yes, both medications are licensed for use in patients with type 2 diabetes and often provide dual benefits of weight loss and improved glycaemic control. Mounjaro is additionally licensed specifically for type 2 diabetes management at lower doses, while Wegovy is licensed solely for weight management.
Will I regain weight after stopping Mounjaro or Wegovy?
Clinical trials demonstrate significant weight regain after discontinuation of both medications, with patients typically regaining approximately two-thirds of lost weight within one year of stopping treatment. This reflects obesity's chronic nature and the need for long-term pharmacological support combined with sustained lifestyle modifications.
Which gives better weight loss results - Mounjaro or Wegovy?
Clinical trials show Mounjaro delivers superior weight loss results compared to Wegovy, with patients losing an average of 21% body weight on the highest dose versus 15% with Wegovy. Cured Pharmacy offers both medications from UK-registered prescribers to help you choose the right treatment.
How do Mounjaro vs Wegovy weight loss results compare in UK studies?
UK real-world data mirrors global trials, showing Mounjaro users typically achieve 15-22% total body weight reduction versus 10-15% with Wegovy over 72 weeks. Cured Pharmacy provides both options with expert clinical support to monitor your progress throughout treatment.
Can I switch from Wegovy to Mounjaro to improve my weight loss results?
Yes, many patients switch from Wegovy to Mounjaro seeking enhanced weight loss results, and your prescriber will create a safe transition plan. Cured Pharmacy's clinical team can assess your current progress and recommend the most effective medication for your weight loss goals.
Is Mounjaro more expensive than Wegovy despite better results?
Mounjaro starts at £124.99 while Wegovy starts at £69.00, but many patients find the superior weight loss results justify the cost difference. Cured Pharmacy offers both at competitive UK prices with £20 off your first order using code Weightlossnew.
How quickly will I see weight loss results comparing Mounjaro vs Wegovy?
Most patients notice initial weight loss within 4-8 weeks on either medication, though Mounjaro often shows faster and greater results during the first 12 weeks. Cured Pharmacy provides ongoing prescription support and guidance to maximise your weight loss results with either treatment option.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 17 July 2026